Continuous Glucose Monitoring (CGM) After Kidney Transplantation

Launched by BO FELDT-RASMUSSEN · Nov 4, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how glucose levels change after kidney transplantation in people who have diabetes, do not have diabetes, or are considered pre-diabetic. The study will use a device called continuous glucose monitoring (CGM) to track glucose levels in patients within 72 hours after their surgery. The main goal is to see how average glucose levels differ among the three groups of participants. A total of 54 people will take part in the study, with 18 people in each group.

To be eligible for this trial, participants must be at least 18 years old and have given their consent before using the CGM. They should be undergoing kidney transplantation and able to cooperate during the first ten days after the surgery. Certain individuals, such as those with allergies to CGM materials or those who have had other organ transplants at the same time, will not be able to participate. Throughout the trial, participants can expect to wear the CGM device, which will help researchers gather important information about their glucose levels and overall health following their transplant.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Written informed consent obtained before CGM application
• • Male or female; age: ≥18 years
• • Kidney transplantation
• Exclusion Criteria:
• • Unable to cooperate to CGM the first ten days after surgery
• • Allergic to plasters in CGM units
• • Combined kidney and liver or pancreatic transplantation
• • Graft loss/rejection within first 48 hours after transplantation